Abstract | BACKGROUND: OBJECTIVE: METHODS: In a prospective controlled study conducted in a tertiary referral hospital, 11 patients with generalized pruritus complicating chronic liver disease were randomized to receive either nalmefene or placebo in a double-blinded fashion for 2-month periods. Scratching activity was measured continuously for 24-hour periods at baseline and at the end of each treatment period. RESULTS: Data on 8 patients who received at least 1 course of nalmefene were available for comparison with corresponding control data, which consisted of observations obtained during a course of placebo and/or at baseline. Nalmefene therapy was associated with a 75% reduction in the geometric mean hourly scratching activity (P <.01) and a decrease in the mean of a visual analogue score of the perception of pruritus in all 8 patients (mean decrease 77%, P <.01). CONCLUSION:
|
Authors | N V Bergasa, D W Alling, T L Talbot, M C Wells, E A Jones |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 41
Issue 3 Pt 1
Pg. 431-4
(Sep 1999)
ISSN: 0190-9622 [Print] United States |
PMID | 10459118
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antipruritics
- Narcotic Antagonists
- Tablets
- Naltrexone
- nalmefene
|
Topics |
- Administration, Oral
- Adult
- Antipruritics
(administration & dosage, adverse effects)
- Cholestasis
(complications)
- Double-Blind Method
- Humans
- Naltrexone
(administration & dosage, adverse effects, analogs & derivatives)
- Narcotic Antagonists
(administration & dosage, adverse effects)
- Pain Measurement
- Pruritus
(drug therapy, etiology)
- Tablets
- Time Factors
|